News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merrion Pharmaceuticals, Inc. Announces Preliminary Results On Phase II Orazol(tm) Study


5/15/2009 9:45:09 AM

DUBLIN, Ireland, May 15, 2009 (GLOBE NEWSWIRE) -- Dr. John Fox, of Merrion Pharmaceuticals ("Merrion" or the "Company"), will address the 7th International Cancer Conference in Dublin today, and will speak about the very positive preliminary results from a multi centre Phase II study on Merrion's Orazol(tm) drug (formerly known as MER 101). The study, conducted in hormone refractory prostate cancer patients with proven bone metastases, enrolled patients at sites in the U.S. and Europe.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES